<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158804</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000362</org_study_id>
    <nct_id>NCT04158804</nct_id>
  </id_info>
  <brief_title>PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT</brief_title>
  <acronym>ProSAVE</acronym>
  <official_title>PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B·R·A·H·M·S GmbH , part of Thermo Fisher Scientific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trials comparing PCT-guided antibiotic algorithms to standard management show a significant&#xD;
      reduction in antibiotic exposure without an increase in mortality or treatment failure.&#xD;
      Despite this strong evidence from multiple studies a recent prospective multicentric&#xD;
      interventional trial in the US fell short of demonstrating antibiotic reductions by&#xD;
      PCT-guided antibiotic management. Amongst other limitations the authors of that study&#xD;
      concluded that successful implementation of PCT may require closer educational oversight. As&#xD;
      such, this study will compare effectiveness and safety of antibiotic prescription guided by a&#xD;
      PCT-algorithm via a Stewardship Team over standard guidelines in hospitalized adult patients&#xD;
      with suspected or confirmed LRTI (including sepsis with respiratory focus).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective</measure>
    <time_frame>30 days</time_frame>
    <description>difference in safety outcomes, antibiotic exposure and healthcare cost between standard of care group and PCT group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite safety adverse event rate at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Composite endpoints include: all-cause in-hospital mortality, all-cause mortality after discharge (as available), hospital readmission, septic shock (vasopressor use for &gt; 1 hour), mechanical ventilation (via endotracheal tube), required dialysis, lung abscess/empyema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>difference in length of hospital stay including ICU duration and resource utilization between standard of care and PCT group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic duration</measure>
    <time_frame>30 days</time_frame>
    <description>Endpoints include: number of patients with short antibiotic treatments (&lt;4 days of antibiotic treatment), antibiotic exposure at discharge, days of therapy per 1000 patients days (inclusive of antibiotics prescribed at discharge)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clostridium difficile infection (CDI)</measure>
    <time_frame>30 days</time_frame>
    <description>Treatment or readmission for CDI until day 30 after discharge</description>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare economic endpoints</measure>
    <time_frame>30 days</time_frame>
    <description>Costs associated with primary hospitalization, readmission for CDI, and loss of function</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Pneumonia, Bacterial</condition>
  <arm_group>
    <arm_group_label>Procalcitonin algorithm+stewardship team</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antibiotic prescription guided by PCT values</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard of care guided by current guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>procalcitonin</intervention_name>
    <description>accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection</description>
    <arm_group_label>Procalcitonin algorithm+stewardship team</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized adult patients ≥ 18 years of age&#xD;
&#xD;
          -  Suspected or confirmed pneumonia &lt;28 days at time of admission to the hospital (ED)&#xD;
             who are prescribed antibiotics&#xD;
&#xD;
          -  Minimum of 2 (two) blood samples available for PCT value assessment within 24 hours of&#xD;
             hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has tested positive for SARS-CoV-2&#xD;
&#xD;
          -  Non-hospitalized patients&#xD;
&#xD;
          -  Major surgeries, defined as any procedure in which an incision is made with the&#xD;
             exception of superficial procedures (eyes, cornea, skin, dental procedures), organs&#xD;
             removed, or normal anatomy altered (e.g. open thoracic, abdominal and/or major&#xD;
             orthopedic surgery), in the past 1 month or expected surgical procedure or patient&#xD;
             receiving antibiotics for surgical prophylaxis&#xD;
&#xD;
          -  Active malignancy and/or active chemotherapy within 3 months&#xD;
&#xD;
          -  Known pregnancy&#xD;
&#xD;
          -  Primary and acquired cell-mediated immune deficiency (HIV with CD4 &lt;350 cells/mm³;&#xD;
             receipt of systemic chemotherapy and/or biologics in the past 3 months for reasons&#xD;
             other than malignancy)&#xD;
&#xD;
          -  Infection where long course antibiotics are the standard of care(&gt;2 weeks) other than&#xD;
             anti-inflammatory reasons.&#xD;
&#xD;
          -  Neutropenia&#xD;
&#xD;
          -  Concomitant non-pulmonary bacterial infection that requires antibiotic therapy based&#xD;
             on an active medical team decision&#xD;
&#xD;
          -  Antibiotics given for non-infectious indications (e.g. rifaximin for hepatic&#xD;
             encephalopathy)&#xD;
&#xD;
          -  Patients with cystic fibrosis&#xD;
&#xD;
          -  Patients receiving dialysis for end-stage renal disease&#xD;
&#xD;
          -  Patients with solid organ transplant, bone marrow transplant or stem cell transplant&#xD;
             recipient&#xD;
&#xD;
          -  ST elevation myocardial infarction&#xD;
&#xD;
          -  Prior enrollment into this study within 30 days&#xD;
&#xD;
          -  Patient experiencing major trauma defined as any injury that could cause prolonged&#xD;
             disability and/or an Injury Severity Score &gt;15, and/or burns or patient under&#xD;
             extracorporeal circulation confirmed by a second research staff member.&#xD;
&#xD;
          -  Patient with acute viral hepatitis and/or decompensated severe liver cirrhosis&#xD;
             (Child-Pugh Class C).&#xD;
&#xD;
          -  Patient with prolonged or severe cardiogenic shock, defined as decreased cardiac&#xD;
             output leading to end organ injury (e.g. severe hypotension or AKI or oliguria or&#xD;
             altered mental status or cool extremities or respiratory distress AND evidence of&#xD;
             metabolic acidosis on lab testing)&#xD;
&#xD;
          -  Patient with pancreatitis, chemical pneumonitis or heat stroke&#xD;
&#xD;
          -  Active infection with invasive fungal pathogen (e.g. candidiasis, aspergillosis) or&#xD;
             plasmodium falciparum malaria or mycobacteria&#xD;
&#xD;
          -  Patient under treatment with OKT3 antibodies, OK-432, interleukins, TNF-alpha and&#xD;
             other drugs stimulating the release of pro-inflammatory cytokines or resulting in&#xD;
             anaphylaxis.&#xD;
&#xD;
          -  Patient is under hospice care&#xD;
&#xD;
          -  Patient with ventilator associated pneumonia&#xD;
&#xD;
          -  Patients with untreated, active, and symptomatic autoimmune disease&#xD;
&#xD;
          -  Patients with empyema, abscess, or cavitary/necrotizing pneumonia&#xD;
&#xD;
          -  Patients actively enrolled in other clinical trial involving immunomodulatory therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael K Mansour, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael K Mansour, MD, PhD</last_name>
    <phone>617-726-6726</phone>
    <email>mkmansour@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Martha's Vineyard Hospital</name>
      <address>
        <city>Oak Bluffs</city>
        <state>Massachusetts</state>
        <zip>02557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore Medical Center</name>
      <address>
        <city>Salem</city>
        <state>Massachusetts</state>
        <zip>01970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Michael K. Mansour</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

